Identifying specific neo-antigens in melanoma, a cancer known for having high numbers of genetic mutations caused by exposure to ultraviolet light, is no easy task. learn more.
Skin cancer prevention advocates can learn from the experiences of two skin cancer prevention programs aimed at identifying opportunities to educate young people about sun safety.
SLNB and GEP combined – powerful predictors of metastatic risk. Learn more on the studies results.
Electronic surface brachytherapy is a low-energy radiation treatment for skin cancer. Radiologists are required to administer the treatment, which is controversial in terms of reimbursement and collaborative requirements.
FDA has approved dinutuximab (Unituxin, United Therapeutics) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk pediatric neuroblastoma patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Dermatologists should learn to recognize some rare and common skin conditions that may result from emerging medical therapies.
Outcomes for patients with Merkel Cell Carcinoma are typically poor and therapeutic options are limited, but advances in understanding the biology of the disease, as well as emerging cutting-edge treatments are expected to improve the outlook, experts say.
Ipilimumab has been evaluated in the adjuvant setting. One expert predicts that ipilimumab’s positive effect on progression-free survival will translate into improvements in overall survival; however, he cautions that there is a risk:benefit ratio to be weighed.
Study finds that treatment with erlotinib may be beneficial in selected head-and-neck squamous-cell carcinoma cases
New agent approvals over the last several years and even better ones in the pipeline have displaced older therapies and improved outcomes for patients with melanoma. Some physicians say, the future may bring a cure.